Back to search
FDAFDA · Food and drugs·Recall number D-0854-2022

Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Fizer Inc, NY, NY 10017, NDC 0009-0068-07.

Published May 18, 2022 · Recall initiated: April 28, 2022

Summary

FDA records drug Class II recall D-0854-2022, published May 18, 2022 and initiated April 28, 2022. Recalling firm: Viatris Inc; Status: Terminated; Reported quantity: 110 bottles; Lot: Lot #: DX7983, exp. date 02/28/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: low out of specification results for dissolution.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Viatris Inc
Distributor
Product was distributed nationwide in the USA
Lot
Lot #: DX7983, exp. date 02/28/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Fizer Inc, NY, NY 10017, NDC 0009-0068-07. recalled?

Yes. FDA published recall D-0854-2022 on May 18, 2022. Reported hazard: Failed Dissolution Specifications: low out of specification results for dissolution.

What should I do if I have this product?

Voluntary: Firm initiated · Letter